Jefferies Reiterates Their Buy Rating on Kamada

By Jason Carr

Jefferies analyst Eun Yang reiterated a Buy rating on Kamada (NASDAQ: KMDA) on October 10 and set a price target of $7. The company’s shares closed yesterday at $4.85.

According to, Yang is a 5-star analyst with an average return of 10.5% and a 57.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Kamada has an analyst consensus of Moderate Buy, with a price target consensus of $7.

The company has a one-year high of $8.61 and a one-year low of $3.75. Currently, Kamada has an average volume of 148.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through two segments: Proprietary Products and Distribution. The Proprietary Products segment develops, manufactures and sells plasma-derived protein therapeutics products. The Distribution segment supplies plasma based products for clinical use.